FMC Of St. Johnsbury Dialysis is a medicare approved dialysis facility center in Saint Johnsbury, Vermont and it has 13 dialysis stations. It is located in Caledonia county at 1080 Hospital Drive, Saint Johnsbury, VT, 05819. You can reach out to the office of FMC Of St. Johnsbury Dialysis at (802) 751-8735. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Of St. Johnsbury Dialysis has the following ownership type - Profit. It was first certified by medicare in July, 2009. The medicare id for this facility is 472501 and it accepts patients under medicare ESRD program.
| Name | FMC Of St. Johnsbury Dialysis |
|---|---|
| Location | 1080 Hospital Drive, Saint Johnsbury, Vermont |
| No. of Dialysis Stations | 13 |
| Medicare ID | 472501 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1080 Hospital Drive, Saint Johnsbury, Vermont, 05819 | |
| (802) 751-8735 | |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
| NPI Number | 1437399094 |
| Organization Name | Fresenius Medical Care St. Johnsbury |
| Doing Business As | Bio-medical Applications Of New Hampshire, Inc. |
| Address | 1080 Hospital Dr St Johnsbury, Vermont, 05819 |
| Phone Number | (802) 751-8735 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 24 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 35 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 358 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Of St. Johnsbury Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 35 |
| Hypercalcemia patient months | 358 |
| Patients with Serumphosphor | 40 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 20 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 21 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 31 |
| Patients with Serumphosphor greater than 7 mg/dL | 20 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 38 |
| Patient months included in arterial venous fistula and catheter summaries | 302 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 66 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 14 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 33 |
| Hospitalization Rate in facility | 98.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 240.3 |
| Hospitalization Rate: Lower Confidence Limit | 43.6 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Of St. Johnsbury Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 15.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 32.9 |
| Readmission Rate: Lower Confidence Limit | 4.5 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Of St. Johnsbury Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.33 (As Expected) |
| SIR: Upper Confidence Limit | 3.21 |
| SIR: Lower Confidence Limit | .42 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Of St. Johnsbury Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 23 |
| Transfusion Rate in facility | 7.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 260.3 |
| Transfusion Rate: Lower Confidence Limit | .3 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Of St. Johnsbury Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 153 |
| Mortality Rate in facility | 16.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 25.4 |
| Mortality Rate: Lower Confidence Limit | 10.5 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago
FMC Of St. Johnsbury Dialysis Location: 1080 Hospital Drive, Saint Johnsbury, Vermont, 05819 Phone: (802) 751-8735 |
News Archive
University of Alabama at Birmingham researchers, for the first time ever, have achieved patch-clamp studies of an elusive part of mammalian myelinated nerves called the Nodes of Ranvier.
It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 8 days ago